Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.

Key facts

Study ID

NCT00676143

Run by

Pfizer

People needed

1100

Starts

2008-01-01

Expected to finish

2012-11-01

Last updated by the study team

2016-06-10

Who can join

Age: 50 and older, up to 88. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
• Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
• Caregiver will participate and be able to attend clinic visits with patient.

You may not qualify if…

• Significant neurological disease other than AD, or a major psychiatric disorder
• Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
• Woman of childbearing potential

Where it is running

• Participant and Clinical Interactions Resources — Birmingham, Alabama, United States
• UAB Clinical Research Pharmacy-Russell Clinic — Birmingham, Alabama, United States
• University of Alabama-Birmingham — Birmingham, Alabama, United States
• Dedicated Clinical Research — Goodyear, Arizona, United States
• Banner Alzheimer's Institute — Phoenix, Arizona, United States
• Jeffrey S. Gitt, DO, PC — Phoenix, Arizona, United States
• The Compounding Center — Phoenix, Arizona, United States
• HOPE Research Institute — Phoenix, Arizona, United States
• Clinical Trials, Inc. — Little Rock, Arkansas, United States
• AC Institute, Incorporated — Carson, California, United States
• Collaborative Neuroscience Network, Inc — Long Beach, California, United States
• San Francisco Clinical Research Center — San Francisco, California, United States
• Alpine Clinical Research Center, Inc. — Boulder, Colorado, United States
• Associated Neurologists, PC — Boulder, Colorado, United States
• Mile HIgh Research Center — Denver, Colorado, United States
• Associated Neurologists of Southern Connecticut, P.C. — Fairfield, Connecticut, United States
• Bendheim Cancer Center — Greenwich, Connecticut, United States
• Center for Healthy Aging — Greenwich, Connecticut, United States
• Alzheimer's Disease Research Unit — New Haven, Connecticut, United States
• Hospital Research Unit — New Haven, Connecticut, United States
• Investigational Drug Service — New Haven, Connecticut, United States
• Moshe Hasbani, MD — New Haven, Connecticut, United States
• Norman S. Werdiger, MD — New Haven, Connecticut, United States
• MR Research Center — New Haven, Connecticut, United States
• Center for Psychiatric Medicine — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.